Ponatinib Is Well Tolerated and Active In Patients With Relapsed/Refractory Philadelphia Positive Acute Lymphoblastic Leukemia (PH+ ALL) and Advanced Phase Of Chronic Myelogenous Leukemia (CML) Harbouring T315I Mutation: The Bologna Experience
Cristina Papayannidis(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), Giovanni Martinelli(University of Bologna), Maria Teresa Bochicchio(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Valentina Robustelli(University of Bologna), Simona Soverini(University of Bologna), Anna Ferrari(University of Bologna), Andrea Ghelli Luserna di Rorà(Fondazione Pisa), Chiara Sartor(University of Bologna), Maria Chiara Abbenante(University of Bologna), Emanuela Ottaviani(University of Bologna), Giuseppe Cimino(Policlinico Umberto I), Silvia Piccari(University of Bologna), Simona Luatti(University of Bologna), Caterina De Benedittis(University of Bologna), Sarah Parisi(University of Bologna), Renato Fanin(University of Udine), Ilaria Iacobucci(St. Jude Children's Research Hospital), Nicoletta Testoni(Thrombolysis in Myocardial Infarction Study Group), Elisa Lani(University of Bologna), Viviana Guadagnuolo(University of Bologna), Carmen Baldazzi(University of Bologna), Federica Frabetti(University of Bologna), Alberto Conficoni(University of Bologna), Cristina Clissa(University of Bologna), Paolo Di Bartolomeo(Martin University), Roberto Di Lorenzo(Gruppo Italiano per il Trapianto di Midollo Osseo), Claudia Venturi(University of Bologna), Stefania Paolini(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola)
Cited by 1
Related Papers
Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia
|New England Journal of Medicine|2014|1.4k
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
|Blood|2015|1.2k
Levofloxacin to Prevent Bacterial Infection in Patients with Cancer and Neutropenia
|New England Journal of Medicine|2005|644
PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia
|Nature Genetics|2019|627